Australia markets closed

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
73.25+0.24 (+0.33%)
At close: 04:00PM EDT
73.39 +0.14 (+0.19%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close73.01
Open73.25
Bid72.00 x 100
Ask77.01 x 100
Day's range73.20 - 73.87
52-week range71.37 - 87.87
Volume8,242,895
Avg. volume7,612,972
Market cap91.253B
Beta (5Y monthly)0.20
PE ratio (TTM)16.28
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.08 (4.21%)
Ex-dividend date14 Mar 2024
1y target estN/A
  • Business Wire

    FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six

    FOSTER CITY, Calif., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.

  • Business Wire

    Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

    FOSTER CITY, Calif. & WALTHAM, Mass., March 28, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

  • Business Wire

    Gilead Sciences Announces Completion of Acquisition of CymaBay

    FOSTER CITY, Calif., March 22, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to br